As of October 27, 2026, Opus Genetics, Inc. is a publicly traded company (Nasdaq: IRD); its largest reported holder is Perceptive Advisors, with 9.99% on Schedule 13G/A of August 14, 2026, then Adage Capital (8.47%). The largest insider holding is Foundation Fighting Blindness Retinal Degeneration Fund, a director, with 3,236,171 shares (3.9% of shares outstanding), per Form 4 of October 2, 2026 (Schedule 13G/A, August 14, 2026).
About to sign with, pay or invest in Opus Genetics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Opus Genetics, Inc. a real, registered company?
- Opus Genetics Inc. files with the SEC under CIK 1228627 (its SEC filings).
- Its shares are listed under the ticker IRD on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Durham, North Carolina, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Opus Genetics, Inc. in our court records and SEC 8-K records (as of 2026-10-27).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Balyasny Asset Management L.P. (filed 2026-08-14).
Who are Opus Genetics, Inc.'s owners and officers?
Opus Genetics, Inc.: incorporated in Delaware; business address in Durham, North Carolina; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Director, Executive Officer (Form D, 2024-11-07)
- : Director, Executive Officer (Form D, 2024-11-07)
- : Executive Officer (Form D, 2024-11-07)
- : Executive Officer (Form D, 2024-11-07)
- : Director (Form D, 2024-11-07)
- : Director (Form D, 2024-11-07)
- : Director (Form D, 2024-11-07)
- : Director (Form D, 2024-11-07)
- : Director (Form D, 2024-11-07)
- : Director (Form D, 2024-11-07)
- : Director (Form D, 2024-11-07)
- : Executive Officer (Form D, 2024-11-07)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 6.64% |
| Schedule 13G/A, 2026-08-14 | Caligan Partners LP | 7.3% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 9.99% |
| Schedule 13D/A, 2026-05-20 | Foundation Fighting Blindness Retinal Degeneration Fund | 4.66% |
| Schedule 13G, 2026-05-15 | Caligan Partners LP | 8.5% |
| Schedule 13G/A, 2026-05-15 | Nantahala Capital Management, LLC | 6.51% |
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G/A, 2026-05-15 | Balyasny Asset Management L.P. | 7.18% |
| Schedule 13G/A, 2026-05-13 | Aaron G.L. Fletcher | 4.53% |
| Schedule 13G, 2026-05-13 | Adage Capital Management, L.P. | 8.47% |
| Schedule 13G/A, 2026-02-17 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G, 2026-02-17 | Balyasny Asset Management L.P. | 7.41% |
Want the whole picture on Opus Genetics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Opus Genetics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Opus Genetics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Opus Genetics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Foundation Fighting Blindness Retinal Degeneration Fund, a director: 3,236,171 shares (3.9% of shares outstanding), on a joint filing (Form 4, 2026-10-02).
- Foundation Fighting Blindness, Inc., a director: 3,236,171 shares (3.9% of shares outstanding), on a joint filing (Form 4, 2026-10-02).
- , a director: 2,883,111 shares (3.5% of shares outstanding), 2,800,111 held directly and 83,000 indirectly (Form 4, 2026-09-08).
- , the chief executive and a director: 2,048,485 shares (2.5% of shares outstanding) (Form 4, 2026-09-11).
- , the president and a director: 704,106 shares (0.85% of shares outstanding) (Form 4, 2026-07-27).
Shares outstanding: 83,195,823 as of 2026-08-03, from the company's latest SEC cover page.
How much has Opus Genetics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-11-07 | $25.78M | $25.78M |
Keep reading
More on Opus Genetics, Inc. and the records around it.
Opus Genetics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Balyasny Asset Management L.P. also filed stake reports on 31 other companies: Beyond Air, Inc. (Aug 2026), Camp4 Therapeutics Corp. (Aug 2026), CELLECTAR BIOSCIENCES, INC. (Aug 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026), Kardigan, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/opus-genetics